ZYBERNO
Stock Report
Updated Aug 31, 2026

FATE THERAPEUTICS INC (FATE)

Healthcare • NASDAQ

$2.43

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
19.0/100
POOR BUSINESS
FATE THERAPEUTICS INC (FATE) scores 19/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-65.1%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.99x)
Operating Margin (Operational Efficiency):CRITICAL (-2,058.1%)
Return on Capital (Capital Efficiency):CRITICAL (-133.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

FATE THERAPEUTICS INC (FATE) stock report — Zyberno Score 19/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, FATE generated -$108.09M in Owner Earnings. Capital was deployed as follows: $5.00M invested in capital expenditures. Reinvestment rate: 6.9%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:2.43
Market Cap:$292.57M

Valuation Multiples (3)

P/B Ratio:1.91x
P/S Ratio:45.07x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$214.44M

Price Action & Momentum (3)

Momentum Percentile:95 / 100
% of 52-Week High:75.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-41.7%
Reinvestment Rate:6.9%
Fundamental Growth Rate (g):-9.2%

Margin Analysis (3)

Operating Margin Ttm:-2,058.1%
Net Margin Ttm:-1,941.1%
Ebitda Margin:-1,865.7%

TTM Performance (2)

Operating Margin Ttm:-2,058.1%
Net Margin Ttm:-1,941.1%

Yield Metrics (2)

Earnings Yield:-$38.89
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-3.4%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-45.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.85x
Quick Ratio:4.85x
Cash Ratio:4.72x

Leverage Analysis (3)

Debt To Equity Ttm:0.99x
Debt-to-Equity Ratio:0.99x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:125,361,000.00
Cash And Cash Equivalents:153,800,000.00
Long Term Debt:$70.75M
Net Debt:-$78.13M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $6.49M
Linear Growth: -45.9%
📊 Click to view full FATE Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$133.59M

Bottom Line Performance (3)

-$126.00M
Income Before Tax:$0.00
Ebitda Ttm:-121,104,000.00

Operating Expenses (5)

Operating Expenses:140,081,000.00
R And D Expense:100,353,000.00
Sga Expense:39,728,000.00
Income Tax Expense:$2.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:4,820.0%
Sga To Revenue Percentage:1,908.2%
Ebitda Margin:-1,865.7%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$260.10M
Current Assets:$157.95M
Ppe Net:51,546,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:106,665,000.00
Current Liabilities:32,592,000.00
Long Term Debt:$70.75M
Short Term Debt:$4.92M

Equity & Capital (3)

Equity:$153.44M
Retained Earnings:-$1.60B
Common Stock:350,000,000.00

Working Capital Items (3)

Accounts Receivable:703,000.00
Inventory:0.00
Accounts Payable:14,904,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:3,518,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$101.91M-$106.91M

Investment Activities (2)

Investing Cash Flow:$23.59M
Capital Expenditures Ttm:4,996,000.00

Financing Activities (3)

Financing Cash Flow:$1.69M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:12,486,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.05
-$1.05
Earnings Per Share Ttm:-$1.05

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.05
Operating Cash Flow Per Share:-$0.88

Book Value & Capital (2)

Book Value Per Share:$1.27
Cash Per Share:1.28

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.02x
Working Capital Turnover Ttm:0.05x

Receivables Management (2)

Receivables Turnover Ttm:9.23x
Days Sales Outstanding Ttm:39.53

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:838.08
Cash Conversion Cycle:-1,797.55
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$108.09M

Damodaran Growth Analysis (2)

Reinvestment Rate:6.9%
Fundamental Growth Rate (g):-9.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-45.9%

Other Growth Rates (1)

Book Value Growth Rate (Linear):-25.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:FATE
Company Name:FATE THERAPEUTICS INC
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:120.40M
Shares Outstanding Basic:120.40M
Shares Outstanding Diluted:120.40M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 06:56:49 UTC
Data Timestamp:2026-08-18T18:48:52.582331
Scroll to Top